Evaluation of Serum Apelin-13 in Psoriasis Vulgaris Patients | ||||
| Benha Journal of Applied Sciences | ||||
| Article 16, Volume 5, Issue 1 part (2), January 2020, Page 293-295 PDF (493.81 K) | ||||
| Document Type: Original Research Papers | ||||
| DOI: 10.21608/bjas.2020.135410 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| S.M. Abdalhady1; EM. Akl1; N.A. Abdalhafeez2; S.M. Nageeb1 | ||||
| 1Dermatology, Venereology and Andrology Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
| 2Clinical Pathology and Immunology Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
| Abstract | ||||
| Psoriasis is a chronic, T-cell mediated inflammatory skin disease with multifactorial etiology. Recent studies support the relation of psoriasis with obesity. Apelin-13 is a novel adipokine that is secreted from white adipose tissue and plays a role in T-cell immunity. In this study, it was aimed to investigate potential relationship between apelin-13 and psoriasis. Serum apelin-13 was measured in 60 patients with moderate to severe psoriasis vulgaris and 30 healthy controls using enzyme-linked immunosorbent assay (ELISA). Serum levels for apelin13 clinched alongside patients with psoriasis vulgaris might have been discovered on make higher over On solid controls (P | ||||
| Keywords | ||||
| Psoriasis vulgaris; Apelin-13 | ||||
|
Statistics Article View: 153 PDF Download: 332 |
||||
